Select Language
Free Registration

Plasma Kallikrein/KLKB1

Plasma Kallikrein/KLKB1 Overview

English NamePlasma kallikreinApproved Drugs4
Drugs in Clinical Trials13Target SynonymEC:3.4.21.34，EC 3.4.21，Fletcher factor，Plasma prekallikrein，KLKB1，Kallikrein B1，Kallikrein B， Plasma (Fletcher Factor) 1，Kininogenin，KLK3，PKK，Plasma Kallikrein，EC 3.4.21.34，PKKD，PPK，PKal，pKAL
Highest Development StageApproved
English NamePlasma kallikrein
Target SynonymEC:3.4.21.34，EC 3.4.21，Fletcher factor，Plasma prekallikrein，KLKB1，Kallikrein B1，Kallikrein B， Plasma (Fletcher Factor) 1，Kininogenin，KLK3，PKK，Plasma Kallikrein，EC 3.4.21.34，PKKD，PPK，PKal，pKAL
Approved Drugs4
Drugs in Clinical Trials13
Highest Development StageApproved

Plasma Kallikrein/KLKB1 Product List

  • Product Category

    Protein (3)

  • Product Status

    Launched (3)

  • Species

    Mouse (1)Human (1)Cynomolgus (1)

  • Tag

    His Tag (3)

  • Conjugate

    Unconjugated (3)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
KL1-H52H9
Human
HEK293
Human Plasma Kallikrein / KLKB1 Protein, His Tag (Pro-form, MALS verified)
KL1-M52H9
Mouse
HEK293
Mouse Plasma Kallikrein / KLKB1 Protein, His Tag (active enzyme)
KL1-C52H3
Cynomolgus
HEK293
Cynomolgus Plasma Kallikrein / KLKB1 Protein, His Tag (active enzyme, MALS verified)
Total: 3
  • 1

Plasma Kallikrein/KLKB1 Background

Human Plasma Kallikrein, a serine protease, is synthesized in the liver and circulates in the plasma by binding to high molecular weight (HMW) kininogen or as a free zymogen. The enzyme cleaves Lys-Arg and Arg-Ser bonds. It activates, in a reciprocal reaction, factor XII after its binding to a negatively charged surface. It also releases bradykinin from HMW kininogen and may also play a role in the renin-angiotensin system by converting prorenin into renin.

Plasma Kallikrein/KLKB1 Synonyms

Fletcher factor,kallikrein B, plasma (Fletcher factor) 1,kininogenin,KLK3 plasma kallikrein,KLKB1,plasma kallikrein heavy chain,plasma kallikrein light chain,Plasma Kallikrein,Plasma Prekallikrein,PPK,KLKB1

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
NavenibartQLS-215; STAR-0215Phase 3 ClinicalQuellis Biosciences IncAngioedemas, Hereditary
Details
ADX-324ADX-324; ADX324Phase 3 ClinicalADARx Pharmaceuticals IncAngioedemas, Hereditary
Details
Lonvoguran ZiclumeranNTLA-2002Phase 3 ClinicalIntellia Therapeutics IncAngioedemas, Hereditary
Details
THR-149TG-758; THR-149Phase 2 ClinicalBicycle Therapeutics, Thrombogenics IncDiabetes Mellitus; Diabetic macular oedema; Diabetic Retinopathy
Details
BW-20805BW-20805; BW20805Phase 2 ClinicalHangzhou Bolin Pharmaceutical Technology Co LtdAngioedemas, Hereditary
Details
MDPK-67bDM-107; MDPK-67; MDPK-67b; MDKP 67b; RIK-7Phase 1 ClinicalMed DiscoveryProstatic Neoplasms
Details
MSB-03MSB-03Phase 1 ClinicalMatriSys Bioscience IncRosacea
Details
AvoralstatBCX-V; BCX-4161Phase 1 ClinicalBiocryst Pharmaceuticals IncAngioedemas, Hereditary; Diabetic macular oedema
Details
ADX-324(Tenacia)ADX324; ADX-324Phase 1 ClinicalYuanyi Biotechnology (Shanghai) Co., Ltd.Angioedemas, Hereditary
Details
ZKLJ-02Phase 1 ClinicalKunming Longjin Pharmaceutical Co LtdCardiovascular Diseases; Ischemic Stroke; Nervous System Diseases; Stroke
Details
ATN-249ATN-249Phase 1 ClinicalAttune PharmaceuticalsAngioedemas, Hereditary
Details
BI-ZClinicalBoehringer Ingelheim Pharma Gmbh & Co KgWet Macular Degeneration
Details
mRNA encoded Cas9 targeting human KLKB 1 gene therapy (Pharma Gateway)ClinicalPharma Gateway ABAngioedemas, Hereditary
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Lanadelumab2372V1TKXK (UNII code); X124-G01; SHP-643; DX-2930; TAK-743ApprovedDyax PharmaTakhzyro, 达泽优United StatesAngioedemas, HereditaryDyax Corp2018-08-23Angioedema; Angioedemas, Hereditary; Coronavirus Disease 2019 (COVID-19); Hereditary Autoinflammatory Diseases; Lung Injury
Details
BerotralstatBCX-7353ApprovedBiocryst Pharmaceuticals IncORLADEYOUnited StatesAngioedemas, HereditaryBiocryst Pharmaceuticals Inc2020-12-03Angioedemas, Hereditary
Details
EcallantideDX-88; EPI-KAL2; FOV-2302; CB-500929ApprovedDyax PharmaKalbitorUnited StatesAngioedemaDyax Corp2009-12-01Angioedema; Angioedemas, Hereditary; Blood Loss, Surgical; Hemorrhage; Hereditary Angioedema Types I and II; Macular Edema; Retinal Vein Occlusion
Details
SebetralstatKVD-900ApprovedVantia Therapeutics Ltd.EkterlyUnited StatesAngioedemas, HereditaryKalvista Pharmaceuticals Ltd, Kalvista Pharmaceuticals Inc2025-07-03Angioedemas, Hereditary
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

order@acrobiosystems.com

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland